Özlem Nalbantoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Özlem Nalbantoğlu has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Behzat Özkan
Department of Pediatric Endocrinology, University of Health Sciences, İzmir Faculty of Medicine, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Turkey
19 shared publications - Özge Köprülü
Department of Pediatric Endocrinology University of Health Sciences, Dr. Behçet Uz Children's Hospital İzmir Turkey
11 shared publications - Hüseyin Anıl Korkmaz
University of Health Sciences, İzmir Faculty of Medicine, Dr. Behçet Uz Children’s Hospital
9 shared publications - Sezer Acar
Division of Pediatric Endocrinology, Dr. Behçet Uz Children’s Education and Research Hospital, Izmir, Turkey
8 shared publications - İbrahim Mert Erbaş
Department of Pediatric Endocrinology, University of Health Sciences, İzmir Faculty of Medicine, Dr. Behçet Uz Children’s Hospital, İzmir, Türkiye
8 shared publications - Tarık Kırkgöz
Department of Pediatrics, Division of Endocrinology, University of Health Sciences, Kayseri City Hospital, Kayseri, Türkiye
7 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 7 (3) , 193-200
Influencing factors on selection of initial treatment dose in children diagnosed with isolated growth hormone deficiency
Objective: In this study, we aimed to reveal the factors that affect the clinician’s preferences in the selection of the starting dose of growth hormone (GH) treatment. Methods: Patients under the age of 18 years who presented to our department between 2013 and 2022, were diagnosed with isolated GH deficiency, and started treatment were included in the study. Relevant data were collected retrospectively from the medical records of the patients. Data are presented as median (interquartile range). Results: Eighty-eight patients (56.8% male; 65.9% prepubertal) with a chronological age (CA) of 10.4 (7.4-12.8) years were included in the study. The median bone age (BA) of the patients was 8 (5-10) years and height standard deviation score (SDS) was -2.7 [(-3.3) – (-2.3)]. Somatropin treatment was started at a median dose of 35 (30-35) µg/kg/day. Patients were divided into two groups according to the treatment dose as 0.05). The initial dose of somatropin correlated negatively with annual growth rate (p=0.006) and positively with the CA−BA difference (p=0.009). Conclusions: Lower pre-treatment annual growth rate was the only factor independently associated with a higher prescribed initial GH dose after adjustment for potential confounders. Although lower target height SDS and greater BA delay were associated with higher prescribed doses in the univariate analyses, these associations were not independently maintained. These findings provide real-world evidence that clinicians primarily rely on auxological severity, particularly impaired growth velocity, when individualizing the initial GH dose in children with isolated GH deficiency.
- 30 September 2026
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 7 (3) , 193-200
Open AccessInfluencing factors on selection of initial treatment dose in children diagnosed with isolated growth hormone deficiency
Objective: In this study, we aimed to reveal the factors that affect the clinician’s preferences in the selection of the starting dose of growth hormone (GH) treatment. Methods: Patients under the age of 18 years who presented to our department between 2013 and 2022, were diagnosed with isolated GH deficiency, and started treatment were included in the study. Relevant data were collected retrospectively from the medical records of the patients. Data are presented as median (interquartile range). Results: Eighty-eight patients (56.8% male; 65.9% prepubertal) with a chronological age (CA) of 10.4 (7.4-12.8) years were included in the study. The median bone age (BA) of the patients was 8 (5-10) years and height standard deviation score (SDS) was -2.7 [(-3.3) – (-2.3)]. Somatropin treatment was started at a median dose of 35 (30-35) µg/kg/day. Patients were divided into two groups according to the treatment dose as 0.05). The initial dose of somatropin correlated negatively with annual growth rate (p=0.006) and positively with the CA−BA difference (p=0.009). Conclusions: Lower pre-treatment annual growth rate was the only factor independently associated with a higher prescribed initial GH dose after adjustment for potential confounders. Although lower target height SDS and greater BA delay were associated with higher prescribed doses in the univariate analyses, these associations were not independently maintained. These findings provide real-world evidence that clinicians primarily rely on auxological severity, particularly impaired growth velocity, when individualizing the initial GH dose in children with isolated GH deficiency.
- 24 August 2026
- Published by Elsevier in Archives de Pédiatrie
- Vol. 33 (7)
Clinical and molecular characterization of 5α-reductase deficiency type 2: First report of a family with homozygous deletion in exon 1 of SRD5A2
- 24 August 2026
- Published by Elsevier in Archives de Pédiatrie
- Vol. 33 (7)
Clinical and molecular characterization of 5α-reductase deficiency type 2: First report of a family with homozygous deletion in exon 1 of SRD5A2
- 12 May 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (6) , 573-581
Genetic evaluation of a group of patients with transient congenital hypothyroidism by targeted exome sequencing
Objectives: Transient congenital hypothyroidism (TCH) is characterized by congenital hypothyroidism (CH) which spontaneously resolves in the first years of life. While most cases are sporadic, several studies from worldwide showed variants in DUOX2 , DUOXA2, TSHR genes in the etiology of TCH. The aim of our study is to evaluate the genetic etiology of TCH. Methods: A total of 54 patients from 50 families with TCH were included the study. The age at diagnosis, age at time of drug discontinuation, gender, consanguinity, the presence of additional examination findings, venous fT4 and TSH levels at the time of diagnosis, at time of drug discontinuation and at the last visit, the follow-up data and genetic characteristics were obtained from records. Results: A total of 54 patients from 50 families [59.3 % male (n=32) and 40.7 % female (n=22)] with TCH were included in the study. Pathogenic variants were detected in 15 out of 54 patients. 10 different DUOX2 variants (c.1060C>T, c.1547G>A, c.2597T>G, c.3314T>C, c.3382C>A, c.3509A>C, c.3790A>G, c.4445C>T, c.28del, c.533G>T) were identified in 11 patients (2 homozygous, 3 compound heterozygous, and 6 heterozygous). Conclusions: Our findings suggest that DUOX2 variants are the main genetic cause of TCH. We reported novel variants in the DUOX2 and TSHR genes that expand their mutational spectrum. These findings support the need for incorporating molecular analysis into the diagnostic evaluation of TCH, not only to improve our knowledge of its genetic underly, but also to provide valuable insights for long-term follow-up, family counseling, and personalized management strategies.
- 12 May 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (6) , 573-581
Genetic evaluation of a group of patients with transient congenital hypothyroidism by targeted exome sequencing
Objectives: Transient congenital hypothyroidism (TCH) is characterized by congenital hypothyroidism (CH) which spontaneously resolves in the first years of life. While most cases are sporadic, several studies from worldwide showed variants in DUOX2 , DUOXA2, TSHR genes in the etiology of TCH. The aim of our study is to evaluate the genetic etiology of TCH. Methods: A total of 54 patients from 50 families with TCH were included the study. The age at diagnosis, age at time of drug discontinuation, gender, consanguinity, the presence of additional examination findings, venous fT4 and TSH levels at the time of diagnosis, at time of drug discontinuation and at the last visit, the follow-up data and genetic characteristics were obtained from records. Results: A total of 54 patients from 50 families [59.3 % male (n=32) and 40.7 % female (n=22)] with TCH were included in the study. Pathogenic variants were detected in 15 out of 54 patients. 10 different DUOX2 variants (c.1060C>T, c.1547G>A, c.2597T>G, c.3314T>C, c.3382C>A, c.3509A>C, c.3790A>G, c.4445C>T, c.28del, c.533G>T) were identified in 11 patients (2 homozygous, 3 compound heterozygous, and 6 heterozygous). Conclusions: Our findings suggest that DUOX2 variants are the main genetic cause of TCH. We reported novel variants in the DUOX2 and TSHR genes that expand their mutational spectrum. These findings support the need for incorporating molecular analysis into the diagnostic evaluation of TCH, not only to improve our knowledge of its genetic underly, but also to provide valuable insights for long-term follow-up, family counseling, and personalized management strategies.
- 26 January 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (3) , 258-264
Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes
Objectives: This study aimed to evaluate changes in fear of hypoglycemia (FOH) and quality of life (QoL) following at least six months of continuous glucose monitoring (CGM) use in the same cohort with type 1 diabetes mellitus (T1DM). Methods: This was a prospective, observational study including first-time CGM users. Auxologic, laboratory, and CGM data was collected. All participants were asked to complete the validated Turkish versions of the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module for both children and parents; the quality of life for youth scale for adolescents; children’s hypoglycemia index (CHI). Results: When pre- and post-CGM scores were compared, the mean total CHI score significantly decreased (p=0.018). Among the subscales, significant reductions were also observed in the “specific situations” (p=0.044) and “behavior scales” (p=0.025) subscales, whereas the “general fears” did not show a significant change (p=0.396). In PedsQL forms, there were no statistically significant differences between pre- and post-CGM total or subscale scores. CGM metrics were also compared between participants who showed improvement in FOH and/or QoL and those who did not. Participants with improvement in FOH had significantly higher sensor active use percentages compared to those without improvement (98.95 vs. 93.0 %, p=0.039). Conclusions: This study’s ability to assess pre- and post-CGM outcomes in the same patients highlights its clinical significance. Our findings suggest that using CGM in children and adolescents with T1DM is associated with a reduction in FOH.
- 26 January 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (3) , 258-264
Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes
Objectives: This study aimed to evaluate changes in fear of hypoglycemia (FOH) and quality of life (QoL) following at least six months of continuous glucose monitoring (CGM) use in the same cohort with type 1 diabetes mellitus (T1DM). Methods: This was a prospective, observational study including first-time CGM users. Auxologic, laboratory, and CGM data was collected. All participants were asked to complete the validated Turkish versions of the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module for both children and parents; the quality of life for youth scale for adolescents; children’s hypoglycemia index (CHI). Results: When pre- and post-CGM scores were compared, the mean total CHI score significantly decreased (p=0.018). Among the subscales, significant reductions were also observed in the “specific situations” (p=0.044) and “behavior scales” (p=0.025) subscales, whereas the “general fears” did not show a significant change (p=0.396). In PedsQL forms, there were no statistically significant differences between pre- and post-CGM total or subscale scores. CGM metrics were also compared between participants who showed improvement in FOH and/or QoL and those who did not. Participants with improvement in FOH had significantly higher sensor active use percentages compared to those without improvement (98.95 vs. 93.0 %, p=0.039). Conclusions: This study’s ability to assess pre- and post-CGM outcomes in the same patients highlights its clinical significance. Our findings suggest that using CGM in children and adolescents with T1DM is associated with a reduction in FOH.
- 2 January 2026
- Published by Taylor & Francis in Endocrine Research
- Vol. 51 (1) , 53-58
Early treatment responses in childhood Graves’ disease: factors affecting the normalization period of thyroid hormones
Herein, we aimed to reveal the factors affecting the early treatment responses and the normalization process of thyroid hormone levels in childhood Graves' disease.. This retrospective study included 46 pediatric patients who were diagnosed with Graves' disease and started treatment during a period of 10 years, and whose at least one of their free T3 (fT3) or free T4 (fT4) levels decreased to the reference range during follow-up. The normalization time of fT3 and fT4 were 5 (3-8) and 3.5 (2-7) weeks after the treatment initiation, respectively. Gender, age, pubertal status, presence of goiter, ophthalmopathy or tachycardia, basal thyroid hormone levels, initial dose of methimazole, and addition of beta-blockers did not show an effect on the normalization time of either fT3 or fT4 (p > 0.05). In those under the age of 12 (n = 15) with a high TRAb titer (>10 IU/L), the time for normalization of fT3 was longer (p = 0.024), and in those with ophthalmopathy, this process was longer for fT4 (p = 0.017). By these results, we showed that early treatment response and the normalization period of thyroid hormones were not related to the initial treatment dose.
- 2 January 2026
- Published by Taylor & Francis in Endocrine Research
- Vol. 51 (1) , 53-58
Early treatment responses in childhood Graves’ disease: factors affecting the normalization period of thyroid hormones
Herein, we aimed to reveal the factors affecting the early treatment responses and the normalization process of thyroid hormone levels in childhood Graves' disease.. This retrospective study included 46 pediatric patients who were diagnosed with Graves' disease and started treatment during a period of 10 years, and whose at least one of their free T3 (fT3) or free T4 (fT4) levels decreased to the reference range during follow-up. The normalization time of fT3 and fT4 were 5 (3-8) and 3.5 (2-7) weeks after the treatment initiation, respectively. Gender, age, pubertal status, presence of goiter, ophthalmopathy or tachycardia, basal thyroid hormone levels, initial dose of methimazole, and addition of beta-blockers did not show an effect on the normalization time of either fT3 or fT4 (p > 0.05). In those under the age of 12 (n = 15) with a high TRAb titer (>10 IU/L), the time for normalization of fT3 was longer (p = 0.024), and in those with ophthalmopathy, this process was longer for fT4 (p = 0.017). By these results, we showed that early treatment response and the normalization period of thyroid hormones were not related to the initial treatment dose.
- Open Access
- 30 December 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (1) , 138-144
Diagnostic Value of Peak-to-Basal Difference or Ratio of Growth Hormone in Children with Growth Hormone Deficiency
Diagnostic Value of Peak-to-Basal Difference or Ratio of Growth Hormone in Children with Growth Hormone Deficiency - Journal of Clinical Research in Pediatric Endocrinology
- 30 December 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (1) , 138-144
Open AccessDiagnostic Value of Peak-to-Basal Difference or Ratio of Growth Hormone in Children with Growth Hormone Deficiency
Diagnostic Value of Peak-to-Basal Difference or Ratio of Growth Hormone in Children with Growth Hormone Deficiency - Journal of Clinical Research in Pediatric Endocrinology
- Open Access
- 1 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (5) , 483-490
Clinical and Laboratory Characteristics of Patients with Genetic Rickets: A Single-Center Experience with Long-Term Outcomes
Objective: Rickets is a metabolic bone disease characterized by inadequate mineralization of growing bone due to a deficiency of calcium, phosphorus, and vitamin D or defects in their metabolism. This study aimed to evaluate the clinical, laboratory, and molecular characteristics and long-term follow-up of the patients diagnosed with genetic rickets. Materials and Methods: This study is designed as a retrospective case series with genetic rickets. The clinical, laboratory, and molecular characteristics of 16 patients, monitored at the Department of Pediatric Endocrinology in Dr. Behçet Uz Children’s Hospital between 2010 and 2024, were analyzed retrospectively. A questionnaire was used to evaluate all clinical, biochemical data related to the diagnosis, treatment, and long-term follow-up. The characteristics of the patients who reached their final height were analyzed. Results: Sixteen patients were included in the study. Six patients had vitamin D–dependent rickets type 1, 2 had vitamin D–dependent rickets type 2, and 8 had hypophosphatemic rickets (HPR). The most common presentation was leg deformities, followed by delayed walking, growth retardation, and alopecia. The mean age at presentation was 3.5 ± 3.1 years. Physical examination findings included short stature, joint widening, genu varum, and genu valgum. The diagnosis of 14 of the cases was confirmed by demonstration of the variants. The mean followup period for the patients was 6.6 ± 4.75 years. The mean final height of the 4 patients, who reached their final height, was 142.07 ± 11.19 cm. Nephrocalcinosis was observed in 2 patients during follow-up. Conclusion: This study provides valuable insights into the clinical and laboratory characteristics, as well as long-term follow-up outcomes of children with genetic rickets. Cite this article as: Köprülü Ö, Özer G, Erbaş IM, Nalbantoğlu Ö, Gürsoy S, Özkan B. Clinical and laboratory characteristics of patients with genetic rickets: A single-center experience with long-term outcomes. Turk Arch Pediatr. 2025;60(5):483-490.
- 1 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (5) , 483-490
Open AccessClinical and Laboratory Characteristics of Patients with Genetic Rickets: A Single-Center Experience with Long-Term Outcomes
Objective: Rickets is a metabolic bone disease characterized by inadequate mineralization of growing bone due to a deficiency of calcium, phosphorus, and vitamin D or defects in their metabolism. This study aimed to evaluate the clinical, laboratory, and molecular characteristics and long-term follow-up of the patients diagnosed with genetic rickets. Materials and Methods: This study is designed as a retrospective case series with genetic rickets. The clinical, laboratory, and molecular characteristics of 16 patients, monitored at the Department of Pediatric Endocrinology in Dr. Behçet Uz Children’s Hospital between 2010 and 2024, were analyzed retrospectively. A questionnaire was used to evaluate all clinical, biochemical data related to the diagnosis, treatment, and long-term follow-up. The characteristics of the patients who reached their final height were analyzed. Results: Sixteen patients were included in the study. Six patients had vitamin D–dependent rickets type 1, 2 had vitamin D–dependent rickets type 2, and 8 had hypophosphatemic rickets (HPR). The most common presentation was leg deformities, followed by delayed walking, growth retardation, and alopecia. The mean age at presentation was 3.5 ± 3.1 years. Physical examination findings included short stature, joint widening, genu varum, and genu valgum. The diagnosis of 14 of the cases was confirmed by demonstration of the variants. The mean followup period for the patients was 6.6 ± 4.75 years. The mean final height of the 4 patients, who reached their final height, was 142.07 ± 11.19 cm. Nephrocalcinosis was observed in 2 patients during follow-up. Conclusion: This study provides valuable insights into the clinical and laboratory characteristics, as well as long-term follow-up outcomes of children with genetic rickets. Cite this article as: Köprülü Ö, Özer G, Erbaş IM, Nalbantoğlu Ö, Gürsoy S, Özkan B. Clinical and laboratory characteristics of patients with genetic rickets: A single-center experience with long-term outcomes. Turk Arch Pediatr. 2025;60(5):483-490.
- 3 June 2025
- Published by S. Karger AG in Molecular Syndromology
- Vol. 17 (1) , 96-100
Pamidronate Treatment of a Patient with Opsismodysplasia and a Novel INPPL1 Variant: Efficacy, Mechanism, and Clinical Outcomes
Introduction: Opsismodysplasia (OPS) is a rare skeletal dysplasia characterized by delayed bone maturation, distinctive skeletal deformities, and severe growth impairment. Mutations in the INPPL1 gene, particularly homozygous variants, are the primary genetic cause of this condition. While bisphosphonate therapy has shown efficacy in OPS cases with hypophosphatemic rickets, its role in cases without this complication remains unclear. Case Presentation: A 2-year-and-2-month-old girl with OPS was treated with intravenous pamidronate (0.5 mg/kg/3 months). Initial evaluations showed severe short stature and low bone mineral density (DEXA SDS: −3.16). After three courses of treatment, the patient achieved independent walking, and her DEXA SDS improved to −2.5 over 1 year. Discussion: Pamidronate is effective in treating OPS even in the absence of hypophosphatemic rickets, showing potential as a therapeutic option for this rare condition.
- 3 June 2025
- Published by S. Karger AG in Molecular Syndromology
- Vol. 17 (1) , 96-100
Pamidronate Treatment of a Patient with Opsismodysplasia and a Novel INPPL1 Variant: Efficacy, Mechanism, and Clinical Outcomes
Introduction: Opsismodysplasia (OPS) is a rare skeletal dysplasia characterized by delayed bone maturation, distinctive skeletal deformities, and severe growth impairment. Mutations in the INPPL1 gene, particularly homozygous variants, are the primary genetic cause of this condition. While bisphosphonate therapy has shown efficacy in OPS cases with hypophosphatemic rickets, its role in cases without this complication remains unclear. Case Presentation: A 2-year-and-2-month-old girl with OPS was treated with intravenous pamidronate (0.5 mg/kg/3 months). Initial evaluations showed severe short stature and low bone mineral density (DEXA SDS: −3.16). After three courses of treatment, the patient achieved independent walking, and her DEXA SDS improved to −2.5 over 1 year. Discussion: Pamidronate is effective in treating OPS even in the absence of hypophosphatemic rickets, showing potential as a therapeutic option for this rare condition.
- Open Access
- 13 November 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220254
Genetic diagnosis of congenital hypopituitarism in Turkish patients by a target gene panel: novel pathogenic variants in GHRHR, GLI2, LHX4 and POU1F1 genes
Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation [...] ABSTRACT Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation
- 13 November 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220254
Open AccessGenetic diagnosis of congenital hypopituitarism in Turkish patients by a target gene panel: novel pathogenic variants in GHRHR, GLI2, LHX4 and POU1F1 genes
Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation [...] ABSTRACT Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation